Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

January 1, 2022

Study Completion Date

September 15, 2024

Conditions
Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma
Interventions
OTHER

Radiation, Surgery or Radiofrequency ablation

Patients with no more than 4 metastases located in less than 3 organs/ lymphatic drainage regions treated with combined systemic therapy and radiation, surgery or radiofrequency.

DRUG

Systemic therapy

"1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy."

Trial Locations (1)

200032

Fudan Universtiy Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT03904927 - Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter